Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor / tezacaftor / vanzacaftor).
07.08.2025 - 17:57:13Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis. This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine.
and www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714775266/en/
